Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00621452
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:39.296911+00:00
Published At
2014-08-06T00:00:00+00:00
Record Updated At
2014-08-06
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["B-cell Chronic Lymphocytic Leukemia", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Splenic Marginal Zone Lymphoma", "Waldenstr\u00f6m Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2014-08-06"
protocolSection.identificationModule.nctId
"NCT00621452"
protocolSection.identificationModule.officialTitle
"A Pilot Study to Evaluate the Safety and Feasibility of Cellular Immunotherapy Using Genetically Modified Autologous CD20-Specific T Cells For Patients With Relapsed or Refractory Mantle Cell and Indolent B Cell Lymphomas"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • B-cell Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (protocolSection.conditionsModule.conditions)
  • Nodal Marginal Zone B-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
  • Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Splenic Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Waldenström Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.